Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 16/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 14/20 | 0.49 |
| ▸ | MBTD1 | Q05BQ5 | 6/20 | 0.49 |
| ▸ | TP53BP1 | Q12888 | 3/20 | 0.46 |
| ▸ | L3MBTL4 | Q8NA19 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10633438 | 0.81 | L3MBTL3 (0.45) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL5175542 | 0.81 | L3MBTL3 (0.45) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| Hydrochloric Acid SCHEMBL5969286 | 0.80 | L3MBTL3 (0.44) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL1242860 | 0.80 | L3MBTL1 (0.38) | L3MBTL1ALDH1A1 | |
| SCHEMBL23542683 | 0.78 | L3MBTL3 (0.47) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| Hydrochloric Acid SCHEMBL3873748 | 0.78 | L3MBTL1 (0.37) | L3MBTL1ALDH1A1 | |
| SCHEMBL1794347 | 0.77 | — | — | |
| SCHEMBL28050578 | 0.76 | L3MBTL3 (0.41) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| Hydrochloric Acid SCHEMBL29772684 | 0.76 | MAPK1 (0.43) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL15681472 | 0.75 | L3MBTL3 (0.41) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7906545-B2 | Prodrugs of CC-1065 analogs | IMMUNOGEN INC. (US) | 2011-03-15 | — | — | US | claimed |
| US-20110008373-A1 | PRODRUGS OF CC-1065 ANALOGS | IMMUNOGEN, INC. (US) | 2011-01-13 | — | — | US | claimed |
| EP-2238988-A1 | Conjugated prodrugs of cc-1065 analogs | ImmunoGen, Inc. (US) | 2010-10-13 | — | — | EP | claimed |
| EP-1492526-B1 | CONJUGATED PRODRUGS OF CC-1065 ANALOGS | IMMUNOGEN INC (US) | 2010-06-16 | — | — | EP | claimed |
| US-7655661-B2 | Prodrugs of CC-1065 analogs | IMMUNOGEN INC. (US) | 2010-02-02 | — | — | US | claimed |
| US-20090281158-A1 | PRODRUGS OF CC-1065 ANALOGS | IMMUNOGEN, INC. (US) | 2009-11-12 | — | — | US | claimed |
| US-7388026-B2 | Prodrugs of CC-1065 analogs | IMMUNOGEN, INC. (US) | 2008-06-17 | — | — | US | claimed |
| US-20070135346-A1 | Prodrugs of CC-1065 analogs | IMMUNOGEN INC. | 2007-06-14 | — | — | US | claimed |
| EP-1492526-A4 | IMPROVED PRODRUGS OF CC-1065 ANALOGS | IMMUNOGEN INC (US) | 2007-03-14 | — | — | EP | claimed |
| US-7049316-B2 | Prodrugs of CC-1065 analogs | IMMUNOGEN INC. (US) | 2006-05-23 | — | — | US | claimed |
| JP-2005532287-A | — | — | 2005-10-27 | — | — | JP | claimed |
| EP-1492526-A2 | IMPROVED PRODRUGS OF CC-1065 ANALOGS | Immunogen, Inc. (US) | 2005-01-05 | — | — | EP | claimed |
| US-20040109867-A1 | Prodrugs of CC-1065 analogs | IMMUNOGEN INC. | 2004-06-10 | — | — | US | claimed |
| WO-2003086318-A2 | IMPROVED PRODRUGS OF CC-1065 ANALOGS | IMMUNOGEN, INC. (US) | 2003-10-23 | — | — | WO | claimed |
| US-20030199519-A1 | Prodrugs of CC-1065 analogs | IMMUNOGEN INC. | 2003-10-23 | — | — | US | claimed |
| EP-0976733-B1 | PROCESS FOR PRODUCING 1-CHLOROCARBONYL-4-PIPERIDINOPIPERIDINE OR HYDROCHLORIDE THEREOF | YAKULT HONSHA KK (JP) | 2003-02-12 | — | — | EP | claimed |
| US-20110280890-A1 | PRODRUGS OF CC-1065 ANALOGS | IMMUNOGEN, INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-8012978-B2 | Prodrugs of CC-A1065 analogs | IMMUNOGEN, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| EP-0660835-A1 | PROCESS FOR PREPARING CERTAIN PYRROLO 3,4- $i(b)]QUINOLINES, CERTAIN 1H-PYRANO 3',4':6,7]INDOLIZINO 1,2-$i(b)]QUINOLIN-3,14(4H,12H)-DIONES, AND CERTAIN 8-METHYL-7-(OXOPROPYL)-INDOLIZINO 1,2-$i(b)]QUINOLIN-9(11H)-ONES | SMITHKLINE BEECHAM CORPORATION (US) | 1995-07-05 | — | — | EP | disclosed |
| WO-1994005672-A1 | PROCESS FOR PREPARING CERTAIN PYRROLO[3,4- b]QUINOLINES, CERTAIN 1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-b]QUINOLIN-3,14(4H,12H)-DIONES, AND CERTAIN 8-METHYL-7-(OXOPROPYL)-INDOLIZINO[1,2-b]QUINOLIN-9(11H)-ONES | SMITHKLINE BEECHAM CORPORATION (US) | 1994-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110280890-A1 | PRODRUGS OF CC-1065 ANALOGS | CASP5, SENP5, CWC15 | L3MBTL3 2882/4885L3MBTL1 2253/4885MBTD1 3263/4885 |
| US-20090281158-A1 | PRODRUGS OF CC-1065 ANALOGS | CASP5, DNPEP, PRCP | L3MBTL3 2653/4885L3MBTL1 2095/4885MBTD1 3336/4885 |
| US-20030199519-A1 | Prodrugs of CC-1065 analogs | CASP5, DNPEP, PRCP | L3MBTL3 2653/4885L3MBTL1 2095/4885MBTD1 3336/4885 |
| US-20110008373-A1 | PRODRUGS OF CC-1065 ANALOGS | CASP5, DNPEP, PRCP | L3MBTL3 2653/4885L3MBTL1 2095/4885MBTD1 3336/4885 |
| US-20040109867-A1 | Prodrugs of CC-1065 analogs | CASP5, DNPEP, PRCP | L3MBTL3 2653/4885L3MBTL1 2095/4885MBTD1 3336/4885 |
| US-20070135346-A1 | Prodrugs of CC-1065 analogs | CASP5, DNPEP, PRCP | L3MBTL3 2653/4885L3MBTL1 2095/4885MBTD1 3336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.